UHS

Universal Health Services Inc

Add to Watchlist

Advanced Chart

165.440

+2.62(1.609%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

166.500

Open

162.110

VWAP

164.85

Vol

1.80M

Mkt Cap

10.66B

Low

161.180

Amount

296.31M

EV/EBITDA(TTM)

6.32

Total Shares

66.93M

15.22B

EV/OCF(TTM)

8.01

P/S(TTM)

0.67

Universal Health Services, Inc. is a holding company. The Company operates, through its subsidiaries, including its management company. It is engaged in owning and operating acute care hospitals and outpatient facilities, and behavioral healthcare facilities. Its segments include acute care hospital services, behavioral health care services, and Other. It owns and operates approximately 359 inpatient facilities, and 60 outpatient and other facilities located in 39 states, Washington, D.C., the United Kingdom, and Puerto Rico. It provides services, which include general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral health services. It also provides capital resources, as well as a variety of management services to its facilities, including information services, finance and control systems, physician recruitment services, and public relations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

4.33B

+5.51%

5.096

+5.29%

4.49B

+9.03%

5.625

+14.33%

4.32B

+9.01%

4.565

+23.05%

Estimates Revision

The market is revising Downward the revenue expectations for Universal Health Services, Inc. (UHS) for FY2025, with the revenue forecasts being adjusted by -0.03% over the past three months. During the same period, the stock price has changed by -5.26%.

Revenue Estimates for FY2025

Revise Downward

-0.03%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.94%

In Past 3 Month

Stock Price

Go Down

-5.26%

In Past 3 Month

11 Analyst Rating

35.20% Upside

Wall Street analysts forecast UHS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UHS is 223.67 USD with a low forecast of 185.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

4 Hold

1 Sell

Moderate Buy

35.20% Upside

Current: 165.440

Low

185.00

Averages

223.67

High

280.00

35.20% Upside

Current: 165.440

Low

185.00

Averages

223.67

High

280.00

Barclays

Overweight

maintain

$257 -> $259

2025-07-30

New

Reason

Barclays

Price Target

$257 -> $259

2025-07-30

New

maintain

Overweight

Reason

Barclays raised the firm's price target on Universal Health to $259 from $257 and keeps an Overweight rating on the shares. The company's core Q2 results missed estimates, but its EBITDA guidance was still raised $80M, the analyst tells investors in a research note.

Cantor Fitzgerald

Neutral

maintain

$227

2025-07-30

New

Reason

Cantor Fitzgerald

Price Target

$227

2025-07-30

New

maintain

Neutral

Reason

Cantor Fitzgerald maintains a Neutral rating on Universal Health with a $227 price target, correcting an earlier research note which incorrected stated the shares were downgraded to Underweight. The company's pathway to EBITDA growth in 2026 versus 2025 is more clear post the Q2 report, excluding the expiration of premium enhanced subsidies on marketplace, the analyst tells investors in a research note. Cantor is now more optimistic on Universal Health's EBITDA growth in 2026 considering the $50M tailwind from Cedar Hill recovery.

Cantor Fitzgerald

Neutral -> Underweight

downgrade

$227

2025-07-29

New

Reason

Cantor Fitzgerald

Price Target

$227

2025-07-29

New

downgrade

Neutral -> Underweight

Reason

Cantor Fitzgerald downgraded Universal Health to Underweight from Neutral with an unchanged price target of $227.

BofA

Joanna Gajuk

Neutral -> Underperform

downgrade

$215 -> $185

2025-07-16

Reason

BofA

Joanna Gajuk

Price Target

$215 -> $185

2025-07-16

downgrade

Neutral -> Underperform

Reason

BofA analyst Joanna Gajuk downgraded Universal Health to Underperform from Neutral with a price target of $185, down from $215.

BofA

Neutral -> Underperform

downgrade

$215 -> $185

2025-07-16

Reason

BofA

Price Target

$215 -> $185

2025-07-16

downgrade

Neutral -> Underperform

Reason

BofA downgraded Universal Health to Underperform from Neutral with a price target of $185, down from $215. The firm downgraded four healthcare facility and managed care stocks that it believes are most exposed to the One Big Beautiful Bill. The bill has a board range of negative implications and creates downside risk to growth estimates for the sector, the analyst tells investors in a research note. The subsidy cuts to Medicaid and Affordable Care Act exchanges are not reflected in consensus estimates and for many companies not reflected in stock prices, contends BofA.

Morgan Stanley

Craig Hettenbach

Equal Weight

maintain

$200

2025-06-04

Reason

Morgan Stanley

Craig Hettenbach

Price Target

$200

2025-06-04

maintain

Equal Weight

Reason

Morgan Stanley analyst Craig Hettenbach hosted a virtual fireside chat with Universal Health CFO Steve Filton and reports that the meeting "highlighted solid underlying utilization trends" in the acute business, with growth in behavioral skewing more toward price. Given sharp stock underperformance, the firm sees "an opportunity for a catchup trade," but adds that volume trends in behavioral and policy outcomes are "key." The firm maintains an Equal Weight rating and $200 price target on Universal Health shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Universal Health Services Inc (UHS.N) is 7.90, compared to its 5-year average forward P/E of 11.86. For a more detailed relative valuation and DCF analysis to assess Universal Health Services Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued

5Y Average PE

11.86

Current PE

7.90

Overvalued PE

13.62

Undervalued PE

10.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued

5Y Average EV/EBITDA

8.02

Current EV/EBITDA

6.07

Overvalued EV/EBITDA

8.84

Undervalued EV/EBITDA

7.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

0.77

Current PS

0.60

Overvalued PS

0.90

Undervalued PS

0.63